Staufen 1 Binding Sites Formed by Duplexing Alu Elements
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective means to identify and modulate targets for Staufen 1 (Stau1) mediated decay (SMD), which is crucial for addressing disorders caused by truncated or nonsense proteins resulting from mutations or aberrant mRNA splicing.
Innovation Solution
The development of methods to identify SMD targets and modulate SMD activity by down-regulating Stau1 or ALU element-containing long noncoding RNAs (lncRNAs), using techniques such as siRNA and co-immunoprecipitation to detect SMD binding sites and screen for agents that affect SMD activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current methods are used to identify SMD targets, then the process is simple, but the ability to effectively identify and modulate targets is insufficient
Solution Approach 1:
The patent introduces Alu element-containing lncRNAs as intermediary molecules that bind to Stau1 protein through duplexing Alu elements. These lncRNAs serve as mediators to facilitate the identification and modulation of SMD targets, enabling more precise target detection while providing a systematic approach to modulate Stau1-mediated mRNA decay activity
Solution Approach 2:
The patent segments the complex SMD identification process into distinct components: (1) Alu element recognition, (2) lncRNA-mediated Stau1 binding, and (3) target mRNA identification. This segmentation allows for systematic screening and modular approach to target discovery, improving identification accuracy through stepwise validation
2Adaptability or versatility
If no specific methods are used to modulate SMD activity, then the approach is simple, but the ability to treat disorders caused by truncated proteins is limited
Solution Approach 1:
Alu element-containing lncRNAs serve as therapeutic intermediaries that can modulate SMD activity by competing for Stau1 binding. These molecules provide a versatile platform for treating disorders caused by truncated proteins, as they can be designed to target specific mRNAs while regulating Stau1-mediated decay pathways
Solution Approach 2:
The patent employs parameter changes in the form of varying lncRNA sequences and Alu element configurations to modulate SMD activity levels. By adjusting the binding affinity and specificity of lncRNAs for Stau1, the system can be tuned to achieve desired therapeutic effects with different degrees of SMD modulation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These methods enable the identification of SMD targets and modulation of SMD activity, potentially treating disorders associated with truncated or erroneous proteins by regulating mRNA decay, thereby addressing the underlying causes of inherited and acquired diseases, including cancers.
Implementation Method 1
down-regulating Stau1 or ALU element-containing long noncoding RNAs (lncRNAs), using techniques such as siRNA
Implementation Method 2
co-immunoprecipitation to detect SMD binding sites
Implementation Method 3
Staufen 1 binding sites formed by duplexing Alu elements
Data Source
AI summary
Disclosed are compositions and methods for identifying binding sites of targets of Stau1-mediated mRNA decay; methods and compositions for treating subjects with conditions resulting from Stau1-mediated mRNA decay, and method of screening for therapeutic agents. Also disclosed is the new pathway as a means for cells to down-regulate the expression of Stau1-binding mRNAs.